SLIGHT IMPROVEMENT FOR ALCHEMIA

Written on the 18 February 2014

SLIGHT IMPROVEMENT FOR ALCHEMIA

 ALCHEMIA Limited (ASX:ACL) has recorded a $5.5 million loss for the half year to December 2013, despite positive clinical trials in oncology overseas.

The drug development company’s loss is an improvement from $5.9 million at this time last year.

Total income dropped to $5 million, down from $9.4 million in the previous period, which included a $4.5 million research and development tax incentive income.

Over the six month period, ACL reduced operating expenses and administrative costs and significantly increased net cash balances from $6.1 million to $16.4 million.

As part of the company’s commercial agreement with Dr Reddy’s Laboratories, there was a $4.7 million profit share in fondaparinux medication in the US.

ACL will continue to treat metatastic colorectal cancer patients in its Phase III HA-Irinotecan clinical study.

Transpacific boosts profit. Read here.

 

BOOK YOUR FUNCTION SPACE HERE

 

 

 

Contact us

Email News Update Sign Up Contact Details
Subscriptions

PO Box 2087
Brisbane QLD 4001

LoginTell a FriendSign Up to Newsletter